Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience has shown promising advancements in its clinical-stage assets, particularly with ALTO-207 (CTC-501), which has achieved consistent high dosing and rapid titration, leading to enhanced tolerability compared to current treatment options, thereby positively impacting treatment outcomes for depressive symptoms. Financially, the company's revenue for FY24 has reached $1.08 billion, a substantial increase of approximately 60% from FY23, indicating strong market demand and effective product performance. Additionally, the introduction of a new transdermal formulation for ALTO-101 that improves safety and pharmacokinetics supports ongoing studies, reinforcing the potential growth and innovation in its precision psychiatry pipeline.

Bears say

Alto Neuroscience Inc's stock has faced persistent pressure since its IPO in 2024, primarily due to the significant failure of its lead asset, ALTO-100, in a pivotal Phase 2b study for major depressive disorder (MDD) in October 2024, compounded by negative results from ALTO-300. This setback raises concerns over the company's ability to effectively target patients with challenging cognitive issues, which could lead to heightened treatment resistance and diminished prospects for successful outcomes. Additionally, the ongoing Phase 2b study in bipolar depression, while a potential avenue for recovery, presents considerable risks with a low probability of success given the company's history of disappointing readouts and the complexities associated with neuroplasticity deficits.

ANRO has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Buy based on their latest research and market trends.

According to 6 analysts, ANRO has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.